COVID-19 Clinical Trial
— Anosmie-COVIDOfficial title:
Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection
Verified date | June 2021 |
Source | Centre Hospitalier Universitaire de Nimes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Loss of sense of smell and taste has been anecdotally reported during the covid-19 epidemic. The study investigators wanted to describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive SARS-CoV-2 infection.
Status | Completed |
Enrollment | 454 |
Est. completion date | November 30, 2020 |
Est. primary completion date | July 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients presenting with COVID-19 related symptoms including: fever, persistent cough, fatigue, shortness of breath, diarrhoea, abdominal pain, chest pain, sore throat, loss of smell or taste - Subjects in prolonged contact with COVID-19 infected patients. Exclusion Criteria: - Patients directly admitted to the intensive care unit were excluded - Patients opposing use of their health data |
Country | Name | City | State |
---|---|---|---|
France | CHU de Nimes | Nîmes |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | SARS-CoV-2 infection status | Positive/negative according to RT-PCR assay | Day 0 | |
Primary | Olfactory and gustatory loss | Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) | Day 0 | |
Secondary | Ability to detect odor | Ability to smell 1.5ml air freshner on a 0-100 VAS scale | Day 0 | |
Secondary | Ability to detect odor | Ability to smell 1.5ml air freshner on a 0-100 VAS scale | Six months | |
Secondary | Ability to detect salty taste | Ability to taste a pinch of table salt on a 0-100 VAS scale | Day 0 | |
Secondary | Ability to detect salty taste | Ability to taste a pinch of table salt on a 0-100 VAS scale | Six months | |
Secondary | Ability to detect sweet taste | Ability to taste a pinch of sugar on a 0-100 VAS scale | Day 0 | |
Secondary | Ability to detect sweet taste | Ability to taste a pinch of sugar on a 0-100 VAS scale | Six months | |
Secondary | Olfactory and gustatory loss | Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) | Day 7 | |
Secondary | Olfactory and gustatory loss | Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) | Day 14 | |
Secondary | Olfactory and gustatory loss | Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) | Day 30 | |
Secondary | Olfactory and gustatory loss | Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) | Day 60 | |
Secondary | Severity of infection according to hospitalization rate | % patients hospitalized | End of study (six months) | |
Secondary | Olfactory and gustatory loss | Custom-designed questionnaire (28 questions pertaining to symptoms, sense of smell and taste) | Six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|